Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 15 2019 - 1:45PM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
OMB APPROVAL
|
OMB Number: 3235-0058
|
|
Estimated average burden hours per response ... 2.50
|
|
SEC FILE NUMBER
|
|
|
CUSIP NUMBER
|
|
(Check one):
|
|
o
Form 10-K
o
Form 20-F
o
Form 11-K
☒
Form 10-Q ☐ Form 10-D
o
Form N-CEN
o
Form N-CSR
|
|
|
|
|
|
For Period Ended:
|
March 31, 2019
|
|
|
|
|
|
o
Transition Report on Form 10-K
|
|
|
|
|
|
o
Transition Report on Form 20-F
|
|
|
|
|
|
o
Transition Report on Form 11-K
|
|
|
|
|
|
o
Transition Report on Form 10-Q
|
|
|
|
|
|
o
Transition Report on Form N-SAR
|
|
|
|
|
|
For the Transition Period Ended:
|
|
Read Instruction (on back page) Before Preparing
Form. Please Print or Type.
Nothing in this form shall be construed to
imply that the Commission has verified any information contained herein.
|
|
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
YEW BIO-PHARM GROUP, INC.
Full Name of Registrant
Former Name if Applicable
9460 Telstar Avenue, Suite 6
Address of Principal Executive Office
(Street
and Number)
El Monte, California 91731
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
¨
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F,11-K, Form N-SAR, or N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed date; and
|
|
|
|
¨
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail the reasons why
Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed
time period.
Information necessary for the filing of a complete
and accurate Form 10-Q could not be gathered and reviewed within the prescribed time period without unreasonable effort and expense
to Registrant
SEC 1344 (03-05)
|
|
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
(Attach extra Sheets if Needed)
PART IV — OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
William B. Barnett
|
|
818
|
|
436-6410
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
|
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
|
Yes ☒ No
o
|
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
Yes
o
No
☒
|
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
YEW BIO PHARM, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date:
|
May 15, 2019
|
By:
|
/s/ Zhigou Wang
|
|
|
|
Name:Zhiguo Wang
President & CEO
|
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or
printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than
an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with
the form.
|
ATTENTION
Intentional misstatements or omissions of
fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)
|
|
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From May 2024 to Jun 2024
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Jun 2023 to Jun 2024